<DOC>
	<DOCNO>NCT02172911</DOCNO>
	<brief_summary>This open-label study evaluate safety , tolerability , immunogenicity INO-3112 DNA vaccine deliver Electroporation female subject HPV-16 and/or 18-positive cervical carcinoma .</brief_summary>
	<brief_title>A Study INO-3112 DNA Vaccine With Electroporation Patients With Cervical Cancer</brief_title>
	<detailed_description>This Phase I/IIa , open-label study evaluate safety , tolerability , immunogenicity INO-3112 [ VGX-3100 INO-9012 ] deliver intramuscularly electroporation approximately 30 female subject biopsy-proven , Stage IB-IVB inoperable invasive cervical carcinoma associate HPV 16 and/or 18 complete treatment standard chemoradiation therapy curative intent ( Cohort 1 ) subject persistent and/or recurrent cervical cancer associate HPV 16 and/or 18 follow salvage therapy ( Cohort 2 ) .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>1 . Written informed consent ; 2 . Histological diagnosis squamous cell carcinoma , adenocarcinoma adenosquamous cell carcinoma cervix . Not accept small cell , clear cell rare variant classical adenocarcinoma ; 3 . Histologically confirm , Stage IBIVB , invasive cervical carcinoma associate HPV 16 and/or 18 meeting follow eligibility criterion either Cohort 1 Cohort 2 ; 1 . Cohort 1 Newly diagnose inoperable cervical cancer treat chemoradiation therapy curative intent life expectancy least 12 month assess investigator No CNS/spinal metastases Able initiate study treatment within 2 week completion last chemoradiation treatment ; 2 . Cohort 2 Persistent and/or recurrent cervical cancer No CNS/spinal metastases Able initiate study treatment least 2 week 4 week completion salvage therapy Subject life expectancy least 12 month assess investigator 4 . ECG clinically significant finding ; 5 . Chemistry , liver function test , renal function , total CPK hematology lab result must ≤ Grade 1 time screening ; 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance status ≤ 1 ; ; 7 . Adequate venous access repeat blood sample accord study schedule ; 8 . Women childbearing potential must negative serum pregnancy test agree remain sexually abstinent , partner sterile ( i.e. , vasectomy ) , use two medically effective method contraception ( e.g. , oral contraception , barrier method , spermicide , intrauterine device ( IUD ) ) ; 9 . Able willing comply study procedure . 1 . Pregnancy breastfeeding ; 2 . History previous therapeutic HPV vaccination ; 3 . Prior exposure investigational agent device within 30 day sign ICF . Of note , subject may participate observational study ; 4 . Positive serological test HIV , Hep B Hep C history HIV infection , Hepatitis B Hepatitis C ( woman cure HCV allow ; subject must serologic test perform within 12 month inform consent ) ; 5 . Prior major surgery subject yet recover baseline ; 6 . High medical risk nonmalignant systemic disease active uncontrolled infection ; 7 . Current malignancy site , exception adequately treat basal squamous cell carcinoma skin ; 8 . Congestive heart failure prior history New York Heart Association ( NYHA ) class III/ IV cardiac disease ; 9 . Use topical corticosteroid near intend administration site ; 10 . Any cardiac preexcitation syndrome ( WolffParkinsonWhite ) ; 11 . History seizure ( unless seizure free 5 year ) ; 12 . Tattoos scar within 2 cm intend site injection implant metal within limb . Any device implant chest ( e.g. , cardiac pacemaker defibrillator ) exclude use deltoid muscle side body ; n ) Active drug alcohol use dependence ; ) Imprisonment compulsory detainment treatment either psychiatric physical ( i.e . infectious disease ) illness ; p ) History immunosuppressive autoimmune disease ; q ) Any illnesses condition opinion investigator may affect safety subject limit evaluation subject study endpoint .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cervical cancer</keyword>
	<keyword>Papillomavirus</keyword>
	<keyword>Chemoradiation</keyword>
	<keyword>Recurrent cervical cancer</keyword>
	<keyword>Persistent cervical cancer</keyword>
</DOC>